American Well (NYSE:AMWL) Upgraded to “Hold” at Wall Street Zen

American Well (NYSE:AMWL) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

A number of other research analysts also recently weighed in on AMWL. Stifel Nicolaus dropped their price target on American Well from $6.00 to $5.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of American Well in a research note on Wednesday, January 21st. Finally, Morgan Stanley decreased their price objective on American Well from $10.50 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.42.

American Well Price Performance

Shares of NYSE AMWL opened at $5.68 on Friday. American Well has a one year low of $3.71 and a one year high of $9.15. The firm has a market cap of $93.97 million, a price-to-earnings ratio of -0.95 and a beta of 1.34. The stock’s fifty day moving average price is $5.09 and its two-hundred day moving average price is $5.16.

American Well (NYSE:AMWL) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.59) by $0.07. The firm had revenue of $55.31 million for the quarter, compared to analyst estimates of $52.71 million. American Well had a negative net margin of 38.38% and a negative return on equity of 35.33%. On average, equities analysts anticipate that American Well will post -9.34 earnings per share for the current fiscal year.

Insider Buying and Selling at American Well

In related news, insider Dmitry Zamansky sold 6,243 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $4.85, for a total value of $30,278.55. Following the transaction, the insider owned 191,468 shares of the company’s stock, valued at approximately $928,619.80. This trade represents a 3.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 10,334 shares of company stock valued at $50,120. Corporate insiders own 11.82% of the company’s stock.

Institutional Investors Weigh In On American Well

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in shares of American Well during the 2nd quarter worth approximately $39,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of American Well during the third quarter valued at approximately $62,000. Engineers Gate Manager LP bought a new stake in American Well during the second quarter worth $101,000. Prelude Capital Management LLC bought a new stake in American Well during the third quarter worth $86,000. Finally, JPMorgan Chase & Co. boosted its position in American Well by 16.5% in the second quarter. JPMorgan Chase & Co. now owns 14,720 shares of the company’s stock worth $131,000 after purchasing an additional 2,081 shares during the last quarter. Hedge funds and other institutional investors own 56.05% of the company’s stock.

About American Well

American Well, operating under the trade name Amwell, is a Boston-based digital health company that develops and delivers telehealth solutions to healthcare providers, payers, employers and patients. Through its cloud-based platform, the company enables secure virtual visits, remote patient monitoring and integrated care coordination across a range of medical disciplines, including primary care, behavioral health, chronic disease management and urgent care.

The company’s core offering, the Amwell Telehealth Platform, facilitates live video consultations, asynchronous messaging, e-prescribing and electronic health record integration.